| 摘要 |
PCT No. PCT/IT96/00063 Sec. 371 Date Nov. 18, 1997 Sec. 102(e) Date Nov. 18, 1997 PCT Filed Apr. 2, 1996 PCT Pub. No. WO96/31210 PCT Pub. Date Oct. 10, 1996Treatment of Parkinson's disease, parkinsonian syndromes, extrapyramidal syndromes, obsessive-compulsive disorder and syndromes, and frontal and subcortical dementias, with imidazo[1,2-a]pyridine-3-acetamide derivatives of the formula (I) <IMAGE> (I) wherein Y represents a hydrogen or halogen atom or a C1-4 alkyl group, A represents naphthyl or C6H3X1X2, wherein each of X1 and X2 independently of one another is a hydrogen or halogen atom, a C1-4 alkoxy group, a C1-6alkyl group or CF3, CH3S- , CH3SO2- or -NO2, and each of R1 and R2 independently of one another represents either a hydrogen atom, or a straight or branched C1-5 alkyl group which is unsubstituted or substituted by one or more halogen atoms, hydroxyl, -N(C1-4 alkyl)2, carbamoyl or C1-4 alkoxy groups, or an allyl group, or a propargyl group, or a C3-6 cycloalkyl group, or a benzyl group, or a phenyl group, not both R1 and R2 being hydrogen, or -NR1R2 represents a heterocyclic ring containing from 3 to 6 carbon atoms, or a heterocyclic ring of the formula <IMAGE>gen or benzyl and R being hydrogen, a C1-4 alkyl group, or phenyl which is unsubstituted or substituted by methoxy or a halogen atom, provided that if Y is 6-chloro, A is not 4-chlorophenyl. |
